274 related articles for article (PubMed ID: 16622794)
1. Development of small molecules designed to modulate protein-protein interactions.
Che Y; Brooks BR; Marshall GR
J Comput Aided Mol Des; 2006 Feb; 20(2):109-30. PubMed ID: 16622794
[TBL] [Abstract][Full Text] [Related]
2. Privileged scaffolds targeting reverse-turn and helix recognition.
Che Y; Marshall GR
Expert Opin Ther Targets; 2008 Jan; 12(1):101-14. PubMed ID: 18076374
[TBL] [Abstract][Full Text] [Related]
3. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction.
Sillerud LO; Larson RS
Curr Protein Pept Sci; 2005 Apr; 6(2):151-69. PubMed ID: 15853652
[TBL] [Abstract][Full Text] [Related]
4. Towards protein surface mimetics.
Fairlie DP; West ML; Wong AK
Curr Med Chem; 1998 Feb; 5(1):29-62. PubMed ID: 9481033
[TBL] [Abstract][Full Text] [Related]
5. Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinases.
Rao FV; Houston DR; Boot RG; Aerts JM; Hodkinson M; Adams DJ; Shiomi K; Omura S; van Aalten DM
Chem Biol; 2005 Jan; 12(1):65-76. PubMed ID: 15664516
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of α-helix-mediated protein-protein interactions using designed molecules.
Azzarito V; Long K; Murphy NS; Wilson AJ
Nat Chem; 2013 Mar; 5(3):161-73. PubMed ID: 23422557
[TBL] [Abstract][Full Text] [Related]
7. Thermodynamics-based drug design: strategies for inhibiting protein-protein interactions.
Schön A; Lam SY; Freire E
Future Med Chem; 2011 Jul; 3(9):1129-37. PubMed ID: 21806377
[TBL] [Abstract][Full Text] [Related]
8. Cyclic and Macrocyclic Peptides as Chemical Tools To Recognise Protein Surfaces and Probe Protein-Protein Interactions.
Cardote TA; Ciulli A
ChemMedChem; 2016 Apr; 11(8):787-94. PubMed ID: 26563831
[TBL] [Abstract][Full Text] [Related]
9. Targeting protein-protein interactions by rational design: mimicry of protein surfaces.
Fletcher S; Hamilton AD
J R Soc Interface; 2006 Apr; 3(7):215-33. PubMed ID: 16849232
[TBL] [Abstract][Full Text] [Related]
10. Use of secondary structure element information in drug design: polypharmacology and conserved motifs in protein-ligand binding and protein-protein interfaces.
Koch O
Future Med Chem; 2011 Apr; 3(6):699-708. PubMed ID: 21554076
[TBL] [Abstract][Full Text] [Related]
11. Protein surface recognition and proteomimetics: mimics of protein surface structure and function.
Fletcher S; Hamilton AD
Curr Opin Chem Biol; 2005 Dec; 9(6):632-8. PubMed ID: 16242379
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein-protein interactions using designed molecules.
Wilson AJ
Chem Soc Rev; 2009 Dec; 38(12):3289-300. PubMed ID: 20449049
[TBL] [Abstract][Full Text] [Related]
13. Helix mimetics as inhibitors of the interaction of the estrogen receptor with coactivator peptides.
Becerril J; Hamilton AD
Angew Chem Int Ed Engl; 2007; 46(24):4471-3. PubMed ID: 17487924
[No Abstract] [Full Text] [Related]
14. Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth.
Pacifico S; Santucci M; Luciani R; Saxena P; Linciano P; Ponterini G; Lauriola A; D'Arca D; Marverti G; Guerrini R; Costi MP
Molecules; 2019 Sep; 24(19):. PubMed ID: 31561530
[TBL] [Abstract][Full Text] [Related]
15. Between a rock and a hard place?
Whitty A; Kumaravel G
Nat Chem Biol; 2006 Mar; 2(3):112-8. PubMed ID: 16484997
[TBL] [Abstract][Full Text] [Related]
16. A novel family of minimal PMRI cyclic peptides as versatile scaffolds for generating new molecular topology.
Gentilucci L; Cardillo G; Tolomelli A; Squassabia F; Tiozzo C
Med Chem; 2006 Jul; 2(4):395-400. PubMed ID: 16848752
[TBL] [Abstract][Full Text] [Related]
17. Scaffolds for blocking protein-protein interactions.
Hershberger SJ; Lee SG; Chmielewski J
Curr Top Med Chem; 2007; 7(10):928-42. PubMed ID: 17508924
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of the structure and intermolecular interactions of a reversible cyclic-peptide inhibitor of the proteasome by NMR spectroscopy and molecular modeling.
Stauch B; Simon B; Basile T; Schneider G; Malek NP; Kalesse M; Carlomagno T
Angew Chem Int Ed Engl; 2010 May; 49(23):3934-8. PubMed ID: 20408152
[No Abstract] [Full Text] [Related]
19. Total synthesis, NMR solution structure, and binding model of the potent histone deacetylase inhibitor FR235222.
Rodriquez M; Terracciano S; Cini E; Settembrini G; Bruno I; Bifulco G; Taddei M; Gomez-Paloma L
Angew Chem Int Ed Engl; 2006 Jan; 45(3):423-7. PubMed ID: 16311994
[No Abstract] [Full Text] [Related]
20. Protein-protein interactions as targets for small-molecule therapeutics in cancer.
White AW; Westwell AD; Brahemi G
Expert Rev Mol Med; 2008 Mar; 10():e8. PubMed ID: 18353193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
